 The main objective of the Action is to improve existing therapies and to find new drugs based on dendrimers  develop new synthetic approaches to tailor dendrimers for specific applications and reducing production costs  preparing a special issue of Current Medicinal Chemistry (IF 4.6) 
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The dendrimer structure
Chemistry and Molecular Sciences and Technologies (CMST)
Working Group 1
Synthesis of Dendrimers
The main object of WG1 is to establish optimum strategies of dendrimer synthesis that ensures high quality products and cost reduction. Particular emphasis is put on environmentally friendly green technologies.
Working Group 2
Characterization of Dendrimers
This WG deals with the characterization of new compounds by experimental and theoretical methods.
Working Group 3
Biological Properties of Dendrimers WG3 concentrates on basic biological studies to determine the biocompatibility and toxicity of new dendrimers as well as their effect on biological systems.
Working Group 4

Medical Applications of Dendrimers
This WG is responsible for exploring new therapeutic strategies and the final implementation of results. There is a cooperation with the pharmaceutical industry.
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